In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...

Microchips in your dog or cat can be a lifesaver because they can reunite a lost pet with an owner. But the closure of one national pet microchip company has left many pet lovers worried after the ...

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

I had just broken a story in Science about the horrific death of a volunteer in a trial of lecanemab, a much-anticipated new drug to treat Alzheimer’s by flushing certain dangerous substances ...

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) has given the green light ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

The Scottish Medicines Consortium (SMC) has rejected a new Alzheimer’s drug, lecanemab (sold under the brand name Leqembi), for use on the NHS in Scotland. The SMC said there were uncertainties about ...